Received Mar 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | X2233 | — |
gave a pediatric dose Hepatitis A to an adult patient; gave a pediatric dose Hepatitis A to an adult patient; 3rd dose of havrix was administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 48-year-old male patient who received HAV (Havrix pediatric) (batch number X2233, expiry date 14-NOV-2025) for prophylaxis. On 13-MAR-2025, the patient received the 3rd dose of Havrix pediatric. On 13-MAR-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: gave a pediatric dose Hepatitis A to an adult patient), underdose (Verbatim: gave a pediatric dose Hepatitis A to an adult patient) and extra dose administered (Verbatim: 3rd dose of havrix was administered). The outcome of the adult use of a child product, underdose and extra dose administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-MAR-2025 The reporter reported that one of staff members gave a pediatric dose Hepatitis A to an adult patient and just needed to call to see what the next dosing will be for the patient? The adult patient received Havrix pediatric vaccine which led to adult use of child product and underdose. And the received dose was 3rd dose of Havrix which led to extra dose administration.